Decaprenyl diphosphate synthase subunit 2 as a prognosis factor in hepatocellular carcinoma

Table 1 Primer sequences

Gene	Forward primer (5'-3')	Reverse primer (5'-3')
E-cadherin	TGCCCAGAAAATGAAAAAGG	GTGTATGTGGCAATGCGTTC
N-cadherin	ACAGTGGCCACCTACAAAGG	CCGAGATGGGGTTGATAATG
Vimentin	GAGAACTTTGCCGTTGAAGC	GCTTCCTGTAGGTGGCAATC
Fibronectin	CAGTGGGAGACCTCGAGAAG	TCCCTCGGAACATCAGAAAC
Cyclin A2	TGCTGGAGCTGCCTTTCATT	TGAAGGTCCATGATACAAGGCT
Cyclin D1	CAGGCGGCTCTTTTTCAC	CCCTCGGTGTCCTACTTCAA
Cyclin D2	CTGTGTGCCACCGACTTTAAGTT	GATGGCTGCTCCCACACTTC
Cyclin D3	TGGATGCTGGAGGTATGTG	CGTGGTCGGTGTAGATGC
PDSS2	GGACTATGCTAAGTTGCGAGAA	GGTCACAGCAAACACAATGT
Confirm FN = fibronectin

PDSS2: Decaprenyl diphosphate synthase subunit 2.

Table 2 Clinicopathologic characteristics and decaprenyl diphosphate synthase subunit 2 expression

Characteristics	n	PDSS2 expression		P value
		Low	High
Group
HCC	33	13	20	0.026
Non-cancerous tissue	33	5	28
Gender
Male	5	2	3	0.6691
Female	28	11	17
Age, yr
≥ 45	21	7	14	0.282
< 45	12	6	6
AFP expression
Normal	18	5	13	0.221
High level	15	8	7
ALT expression
Normal	17	7	10	0.556
High level	16	6	10
HbsAg
Positive	21	9	12	0.436
Negative	12	4	8
Tumor size
≥ 5 cm	20	5	15	0.004
< 5 cm	13	8	5
Differentiation
Well	19	4	15	0.015
Poor	14	9	5
Clinical stage
I + II	18	3	15	0.005
III + IV	15	10	5

AFP: Alpha fetoprotein; ALT: Alanine aminotransferase; HbsAg: Hepatitis B surface antigen; HCC: Hepatocellular carcinoma; PDSS2: Decaprenyl diphosphate synthase subunit 2.